Desmopressin enhances the binding of plasma von Willebrand factor to collagen in plasmas from normal dogs and dogs with type I von Willebrand's disease.
A new in vitro von Willebrand factor-collagen binding activity (vWF:CBA) assay was used to assess qualitative changes in vWF in normal dogs and dogs with Type I von Willebrand's disease (vWD) following treatment with desmopressin acetate (DDAVP). Although DDAVP induced increases in vWF antigen concentrations at 1 hour postinfusion in both normal and vWD dogs (57% and 60% increases, respectively), there were disproportionately greater increases in vWF:CBA (96% and 103% increases). These results support the hypothesis that the enhanced hemostatic activity induced by DDAVP is, at least in part, due to the selective release of more functionally active vWF multimers. The assay, as described, provides a convenient means of simultaneously assessing vWF quantity and function before and after DDAVP administration.
Johnstone
I B
IB
Department of Biomedical Sciences, University of Guelph, Ontario.
D000818:Animals; D000941:Antigens / Q000097:blood*; D003094:Collagen / Q000378:metabolism*; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy*; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D007262:Infusions, Intravenous; D012076:Renal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D014841:von Willebrand Factor / Q000378:metabolism*
D000941:Antigens; D012076:Renal Agents; C029417:Von Willebrand antigen; D014841:von Willebrand Factor; D003094:Collagen; D003894:Deamino Arginine Vasopressin